wq
FORPRESCRIBERS 1ST EDITION BY LUO
wq w
q wq wq wq wq
KAYINGO TEST BANK | 2024 UPDATE
wq wq wq wq wq wq
, Table of Contents wq wq
Chapter w q 1: w q An Introduction to
w q w q w q Evidence-Based Clinical w q w q Practice Guidelines ........................................3
w q
Chapter w q 2: Pharmacokinetics
w q w q /Chapter3: Pharmacodynamics ......................................................................... 13
w q
Chapter4: Pharmacogenetics w q w q and Pharmacogenomics ........................................................................................ 25
w q
Chapter w q 5: Pharmacology
w q w q Across w q the Life Span ........................................................................................ 30
w q w q
Chapter w q 6: Drug-Therapy Prescribing in Special
w q w q w q w q w q Populations .................................................................... 36
Chapter w q 7: Drug Development
w q w q w q and Approval............................................................................................... 45
w q
Chapter 8-Chapter 10: Foundations of Prescription Writing Chapter 9: ResponsibleControlled-
w q w q w q w q w q w q w q w q w q
Substance Prescribing Chapter 10: Antibiotic Stewardship ............................................................................. 51
wq w q w q w q w q w q
Chapter w q 11: Applied Calculations
w q w q w q for w q Prescribing ....................................................................................... 58
Chapter 12-: Promoting Adherence With Pharmacotherapy II: System-Specific and Patient-Focused
w q w q w q w q w q w q w q w q w q
Prescribing Chapter 13: Pharmacotherapy for Ear, Nose, Mouth, andThroat Conditions /Chapter
wq w q w q w q w q w q w q w q w q w q w q
14: Pharmacotherapy for Eye Conditions ......................................................................................................... 67
w q wq w q w q w q
Chapter w q 15: Pharmacotherapy for
w q w q w q Skin w q Conditions ..................................................................................... 74
Chapter w q 16: Pharmacotherapy for
w q w q w q Neurologic w q Conditions ........................................................................... 81
Chapter w q 17: Pharmacotherapy for
w q w q w q Cardiovascular w q Conditions .................................................................... 94
Chapter w q 18: Pharmacotherapy for
w q w q w q Respiratory Conditions ........................................................................ 106
w q
Chapter 19: Pharmacotherapy for Gastrointestinal Conditions and Conditions RequiringNutritional
w q w q w q w q w q w q w q w q
Support.................................................................................................................................................................... 117
wq
Chapter w q 20: Pharmacotherapy for
w q w q w q Genitourinary Conditions ..................................................................... 128
w q
Chapter w q 21: Pharmacotherapy for
w q w q w q Renal, w q Acid–Base, w q Fluid, w q and Electrolyte Disorders ................. 133
w q w q
Chapter w q 22: Pharmacotherapy for
w q w q w q Musculoskeletal and Rheumatologic w q w q w q Conditions ........................... 146
Chapter w q 23: Therapeutic
w q w q Applications w q of w q Immunology and w q w q Vaccines ............................................... 158
Chapter w q 24: Pharmacotherapy
w q w q for w q Endocrine Disorders ............................................................................ 163
w q
Chapter w q 25: Pharmacotherapy for
w q w q w q Hematologic w q Disorders.......................................................................... 174
Chapter w q 26: Hematology/Oncology and Supportive
w q w q w q w q Care for w q w q the Nononcologist .............................. 190
w q
Chapter w q 27: Pharmacotherapyw q w q Related w q to Women’s w q w q Health w q Conditions ............................................. 196
Chapter w q 28: Pharmacotherapy Related to Men’s
w q w q w q w q w q Health w q Conditions .................................................... 211
Chapter w q 29: Pharmacotherapy w q w q Related w q to Transgender
w q w q Care ................................................................. 217
Chapter w q 30: Antimicrobial
w q w q Pharmacotherapy ................................................................................................... 224
Chapter w q 31: Antiretroviral Pharmacotherapy ................................................................................................... 235
w q w q
Chapter 32: Psychopharmacology and Integrative Health: Combined Treatment ofPsychiatric and
w q w q w q w q w q w q w q w q w q
Neurocognitive Conditions ................................................................................................................................... 247
wq w q
Chapter w q 33: Pharmacotherapy for
w q w q w q Pain Management................................................................................. 257
w q
Chapter w q 34: Substancew q w q Use Disorder w q w q III: Health Promotion and Maintenance ................................ 267
w q w q w q w q
Chapter w q 35: Over-the-Counter
w q w q Medications ..................................................................................................... 283
Chapter w q 36: Pharmacotherapy for
w q w q w q Obesity .................................................................................................... 291
, Chapter 1: An Introduction to Evidence-Based Clinical Practice Guidelines
w q w q w q w q w q w q w q w q
MULTIPLE CHOICE w q
• What is the primary purpose
w q w q w q w q w q of the nursing
w q w q w q assessment?
A. Identifying underlying pathologic w q w q w q conditions
B. Assisting w q the physician in identifying medical conditions
w q w q w q w q w q
C. Determining the patients mental status w q w q w q w q
D. Exploring patient responses to w q w q w q w q health w q problems
ANS: D w q
A nursing assessment is done to identify the patients response
w q w q w q w q w q w q w q w q w q
to health problems. During the nursing assessment phase, a
w q wq w q w q w q w q w q w q w q
comprehensive information base is developed through a physical
wq w q w q w q w q w q w q w q
examination, nursing history, medication history, and professional
wq w q w q w q w q w q w q
observation. Identifying underlying pathologic conditions and
wq w q w q w q w q w q
assisting the physician in identifying medical conditions is not
w q wq w q w q w q w q w q w q w q
part of the nursing process. Determining the patients mental
w q w q w q wq w q w q w q w q w q
status is one part of the nursing assessment, but it is
w q w q w q w q wq w q w q w q w q w q w q
w not the primary purpose.
q w q w q w q
DIF: Cognitive Level:w q w q
Comprehension REF: dm 36 OBJ: 1 w q w q w q w q w q
| 3 TOP: Nursing Process Step:
w q w q w q w q w q
Assessment
MSC: NCLEX Client Needs Category:
w q w q w q w q w q Health Promotion and w q w q w q Maintenance
• What is the basis w q w q w q w q of the NANDA I w q w q wq w q taxonomy?
A. Functional health patterns w q w q
B. Human response w q w q patterns
C. Basic w q human needs w q
D. Pathophysiologic w q needs
ANS: B w q
The NANDA I taxonomy identifies human response patterns.
w q w q w q w q w q w q w q
Functional components of health patterns are limited to activity, fluid
wq wq wq wq wq wq wq wq wq wq
volume, nutrition, self care, and sensory perception. Basic
wq w q w q w q w q w q w q w q
human needs comprise
w q less than merely health patterns.
wq wq w q wq wq wq wq
Pathophysiologic needs are not part of the scope of NANDA
w q w q w q w q w q w q w q w q w q w q
I.
w q
, DIF: Cognitive Level: Knowledge
wq w q wq
REF: pp. 37-38 OBJ: 5 TOP:
wq w q w q w q w q w q
Nursing Process Step: Diagnosis w q w q w q
MSC: NCLEX Client Needs Category: Physiological
w q w q w q w q w q w q Integrity
• Which task is included w q w q w q w q in the assessment step
w q w q w q w q of the nursingw q w q w q process?
A. Establishing w q patient w q goals/outcomes
B. Implementing the w q w q nursing care plan w q w q w q (NCP)
C. Measuring goal/outcome achievement w q w q
D. Collecting and w q w q communicating w q data
ANS: D w q
Data are collected and communicated in the assessment phase of
w q w q w q w q w q w q w q w q w q
the nursing process. Establishing goals is the function of
w q wq w q w q w q w q w q w q w q
planning.
w q
Implementing the NCP is the function of implementation. w q w q w q w q w q w q w q
Measuring outcome achievement is the function of evaluation.
w q wq w q w q w q w q w q w q
DIF: Cognitive Level:
w q w q
Comprehension REF: dm 36 OBJ: 2 w q w q w q w q w q
| 3 TOP: Nursing Process Step:
w q w q w q w q w q
Assessment
MSC: NCLEX Client Needs Category:
w q w q w q w q w q Health Promotion and w q w q w q Maintenance
• Which statement regarding w q w q w q nursing diagnoses w q w q is w q accurate?
a. Nursing diagnoses remain the same for as w q w q w q w q w q w q w q long as the disease
w q w q w q w q is
present. w q
b. Nursing diagnoses are written to identify disease states. w q w q w q w q w q w q w q
c. Nursing diagnoses describe patient problems that nurses w q w q w q w q w q w q w q treat.
d. Nursing diagnoses w q w q identify causes related to illness. w q w q w q w q
ANS: C w q
Diagnostic statements identify problems a nurse is independently
w q w q w q w q w q w q w q
able to treat within the scope of professional practice. Nursing
w q wq w q w q w q w q w q w q w q w q
diagnoses vary with the changing condition of the patient. The
w q wq w q w q w q w q w q w q w q w q
response patterns are unique to the patient and are not disease
w q wq w q w q w q w q w q w q w q w q w q
specific.
w q
Nursing diagnoses describe the patients human response pattern.
w q w q w q w q w q w q w q
wq DIF: Cognitive Level: Comprehension
w q w q w q